PHARMACOKINETICS OF SUBCUTANEOUS RECOMBINANT INTERLEUKIN-2 ADMINISTRATION IN CANCER-PATIENTS

被引：0
|
作者：
CARUSO, B
GIAVARINA, D
JIRILLO, A
GIAVARINA, M
BALLI, M
机构：
[1] LEGNAGO HOSP,CLIN CHEM LAB,VERONA,ITALY
[2] LEGNAGO HOSP,DEPT RADIOTHERAPY & ONCOL,VERONA,ITALY
来源：
EOS-RIVISTA DI IMMUNOLOGIA ED IMMUNOFARMACOLOGIA | 1992年 / 12卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Data from a clinical trial with recombinant Interleukin (rIL-2) subcutaneousy administered are here reported. Five patients with cancer were administered with r-IL2. Serum levels were measured on serial samples by immunoenzymatic method. This method is easier than biological methods, allowing to measure rIL-2 only as antigen. Therefore, immunoenzymatic method can be on support in the comprehensive study of IL-2 farmacokynetic. rIL-2 was detectable in serum in all the patient treated, with different levels and time.
引用
收藏
页码：207 / 209
页数：3
相关论文
共 50 条
  • [1] PHARMACOKINETICS OF TECELEUKIN (RECOMBINANT HUMAN INTERLEUKIN-2) AFTER INTRAVENOUS OR SUBCUTANEOUS ADMINISTRATION TO PATIENTS WITH CANCER
    GUSTAVSON, LE
    NADEAU, RW
    OLDFIELD, NF
    JOURNAL OF BIOLOGICAL RESPONSE MODIFIERS, 1989, 8 (04): : 440 - 449
  • [2] NEUROENDOCRINE EFFECTS OF SUBCUTANEOUS INTERLEUKIN-2 INJECTION IN CANCER-PATIENTS
    LISSONI, P
    BARNI, S
    ROVELLI, F
    CRISPINO, S
    FUMAGALLI, G
    PESCIA, S
    VAGHI, M
    CAMESASCA, G
    TANCINI, G
    TUMORI, 1991, 77 (03) : 212 - 215
  • [3] EFFECTS OF INTERLEUKIN-2 ADMINISTRATION ON PLATELET-FUNCTION IN CANCER-PATIENTS
    OLEKSOWICZ, L
    ZUCKERMAN, D
    MROWIEC, Z
    PUSZKIN, E
    DUTCHER, JP
    AMERICAN JOURNAL OF HEMATOLOGY, 1994, 45 (03) : 224 - 231
  • [4] ALTERED TRYPTOPHAN AND NEOPTERIN METABOLISM IN CANCER-PATIENTS TREATED WITH RECOMBINANT INTERLEUKIN-2
    BROWN, RR
    LEE, CM
    KOHLER, PC
    HANK, JA
    STORER, BE
    SONDEL, PM
    CANCER RESEARCH, 1989, 49 (17) : 4941 - 4944
  • [5] CONCOMITANT ADMINISTRATION OF RECOMBINANT HUMAN INTERLEUKIN-2 AND RECOMBINANT INTERFERON-ALPHA-2A IN CANCER-PATIENTS - A PHASE-I STUDY
    LEE, KH
    TALPAZ, M
    ROTHBERG, JM
    MURRAY, JL
    PAPADOPOULOS, N
    PLAGER, C
    BENJAMIN, R
    LEVITT, D
    GUTTERMAN, J
    JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) : 1726 - 1732
  • [6] TREATMENT OF METASTATIC RENAL-CELL CANCER-PATIENTS WITH RECOMBINANT SUBCUTANEOUS HUMAN INTERLEUKIN-2 AND INTERFERON-ALPHA
    ATZPODIEN, J
    KORFER, A
    PALMER, PA
    FRANKS, CR
    POLIWODA, H
    KIRCHNER, H
    ANNALS OF ONCOLOGY, 1990, 1 (05) : 377 - 378
  • [7] Subcutaneous administration of recombinant glycosylated interleukin 6 in patients with cancer: Pharmacokinetics, pharmacodynamics and immunomodulatory effects
    Banks, RE
    Forbes, MA
    Patel, PM
    Storr, M
    Hallam, S
    Clarke, D
    Novick, D
    Ingham, E
    Bowmer, C
    Southgate, J
    Trejdosiewicz, LK
    Illingworth, J
    Perren, TJ
    Selby, PJ
    CYTOKINE, 2000, 12 (04) : 388 - 396
  • [8] SYSTEMIC ADMINISTRATION OF RECOMBINANT METHIONYL HUMAN INTERLEUKIN-2 (ALA-125) TO CANCER-PATIENTS - CLINICAL-RESULTS
    SARNA, GP
    FIGLIN, RA
    PERTCHECK, M
    ALTROCK, B
    KRADJIAN, SA
    JOURNAL OF BIOLOGICAL RESPONSE MODIFIERS, 1989, 8 (01): : 16 - 24
  • [9] PHARMACOKINETICS OF RECOMBINANT INTERLEUKIN-2 IN HUMANS
    KONRAD, MW
    HEMSTREET, G
    HERSH, EM
    MANSELL, PWA
    MERTELSMANN, R
    KOLITZ, JE
    BRADLEY, EC
    CANCER RESEARCH, 1990, 50 (07) : 2009 - 2017
  • [10] Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application
    Kirchner, GI
    Franzke, A
    Buer, J
    Beil, W
    Probst-Kepper, M
    Wittke, F
    Övermann, K
    Lassmann, S
    Hoffmann, R
    Kirchner, H
    Ganser, A
    Atzpodien, J
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 46 (01) : 5 - 10
12345